LBF20406AM04: Difference between revisions
No edit summary |
No edit summary |
||
(18 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
Line 4: | Line 6: | ||
|LipidBank=XPR7020 | |LipidBank=XPR7020 | ||
|LipidMaps=LMFA08020006 | |LipidMaps=LMFA08020006 | ||
|SysName=N- | |SysName=N-Ethyl- (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine | ||
|Common Name=&&N- | |Common Name=&&N-Ethylarachidonoylamide&&N-Ethyl- (5Z,8Z,11Z,14Z) -eicosatetraenoylamine&& | ||
|Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | ||
|NMR Spectra= | |NMR Spectra=^1 H NMR (CDCl3) delta 5.31-5.41 (m, 8H), 3.22-3.34 (m, 2H), 2.78-2.84 (m, 6H), 1.68-1.78 (m, 4H), 1.22-1.40 (m, 6H), 1.13 (t, J=7.3, 3H), 0.88 (t, J=7.1H, 3H) [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | ||
|Source= | |||
|Chemical Synthesis=This compound was synthesized from arachidonoyl chloride and ethylamine, yield is 73 %. [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |||
|Metabolism= | |||
|Biological Activity=Binding of this compound to the brain cannabinoid receptor (CB1), Ki (nM)= 34.0±2.7 [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |||
}} | }} | ||
{{Lipid/Footer}} |
Latest revision as of 04:39, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR7020 |
LipidMaps | LMFA08020006 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20406AM04 |
N-Ethylarachidonoylamide | |
---|---|
Structural Information | |
N-Ethyl- (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine | |
| |
Formula | C22H37NO |
Exact Mass | 331.287514811 |
Average Mass | 331.53532 |
SMILES | C(CCC(NCC)=O)C=CCC=CCC=CCC=CCCCCC |
Physicochemical Information | |
colorless oil Sheskin_T et al. | |
This compound was synthesized from arachidonoyl chloride and ethylamine, yield is 73 %. Sheskin_T et al. | |
Binding of this compound to the brain cannabinoid receptor (CB1), Ki (nM)= 34.0±2.7 Sheskin_T et al. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | 1H NMR (CDCl3) δ 5.31-5.41 (m, 8H), 3.22-3.34 (m, 2H), 2.78-2.84 (m, 6H), 1.68-1.78 (m, 4H), 1.22-1.40 (m, 6H), 1.13 (t, J=7.3, 3H), 0.88 (t, J=7.1H, 3H) SheskinTet al. |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|